Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

Schizophrenia Clinical Trial

Official title:

A Randomized, Double-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LB-102 Administered Orally to Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04187560
• Other study ID #: LB-102-001
• Status: Completed
• Phase: Phase 1
• Start date: January 22, 2020
• Est. completion date: November 9, 2020

Study information

• Verified date: December 2020
• Source: LB Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study of LB-102 N-Methyl amisulpride) in healthy volunteers. The primary objective is to evaluate the safety and the tolerability of a single oral dose (SAD) and multiple oral doses (MAD) of LB-102 as compared to placebo. The secondary objectives are to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of LB-102.

Description:

This is a Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of LB-102 in healthy subjects. The study will consist of two parts: Part A - Single Ascending Dose and Part B - Multiple Ascending Doses. There will be 5 cohorts in Part A and 3 Cohorts in Part B of this study. Each cohort consists of 8 subjects, with 6 subjects assigned to LB-102 and 2 subjects assigned to placebo. In Parts A and B, eligible subjects will be randomized on Day 1 (pre-dose) to placebo (n=2) or LB-102 (n=6). Eligible subjects will receive 1 dose on Day 1 (Part A) or 13 doses on Days 1-7 (Part B) of placebo or LB-102.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: November 9, 2020
• Est. primary completion date: July 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

Subjects may be included in the study only if they meet all of the following criteria:

1. Competent to provide informed consent.

2. Voluntarily provide informed consent.

3. Healthy adult male and female subjects between 18 to 55 years of age inclusive at the screening visit.

4. Body Mass Index (BMI) = 18 and = 30 kg/m2 at screening visit.

5. Subjects must be in good general health as determined by medical history and physical examination with no clinically significant medical findings and no history of significant medical disease (e.g. cardiovascular, pulmonary, renal, etc.) or acute condition with the past 30 days.

6. Have normal clinical laboratory test results and ECG, which are not considered to be clinically significant by the investigator.

7. Female subjects of child-bearing potential must agree to use two methods of an acceptable method of birth control (e.g., condom and spermicide, intrauterine device (IUD), oral contraception which has been stable for 30 days) and at least 90 days after stopping the investigational product. Female subjects using oral contraception whose partner consistently uses condoms or who is vasectomized is also acceptable.

8. Male subjects must be surgically sterile or practicing at least one method of contraception, from initial study drug administration through 90 days after

administration of the last dose of study drug:

9. Male subjects must agree to abstain from sperm donation through 90 days after administration of the last dose of investigational drug. Exclusion Criteria:

Subjects will be excluded from the study for any of the following reasons:

1. Are pregnant or lactating.

2. Have a history or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders which, in the opinion of the investigator, increases the risk of the study drug or may confound the interpretation of study measures.

3. Clinically significant abnormal findings on physical examination, vital signs, or ECG.

4. History or presence of psychiatric or neurological disease or condition.

5. History of seizures.

6. Subject with any history or current evidence of suicidal behavior.

7. Unwilling to complete any planned study assessments, including the Columbia-Suicide Severity Rating Scale (CSSRS).

8. Recent history of alcohol or drug abuse (within the last two years).

9. Any use of tobacco or tobacco-containing products (cigarettes, pipes, etc.) within one month prior to screening.

10. Have a history of blood donation in excess of 500 mL of blood within 30 days prior to Screening.

11. Have received treatment with an investigational drug or device within 30 days prior to Screening.

12. Use of any prescription or over the counter medication, herbal medications, vitamins, or supplements within 14 days prior to study drug administration.

13. Have a positive test for human immunodeficiency virus (HIV) antibodies 1 and 2, Hepatitis B surface antigen or Hepatitis C antibody.

14. Any subject who is known to be allergic to the study drug or any components of the study drug.

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• LB-102
(N-Methyl amisulpride)

Locations

Country	Name	City	State
United States	Medpace Clinical Pharmacology LLC	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
LB Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants who experience at least one treatment-emergent adverse event (TEAE)	A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing.	Day 8 (Part A) or Day 15 (Part B)
Secondary	Tmax: Time to Reach the Maximum Plasma Concentration	Time to reach the maximum observed plasma concentration for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7).	Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)
Secondary	Cmax: Maximum Observed Plasma Concentration	Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Cmax will be measured for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7).	Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)
Secondary	AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration	AUC(0-tlqc) is a measure of total plasma exposure to a drug from time 0 to time of the Last Quantifiable Concentration and will be measured for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7)	Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)
Secondary	AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose	AUC(0-24) is a measure of total plasma exposure to the drug from Time 0 to 24 hours post-dose for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 14).	Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B)

External Links

•   Corporate Website